‘STeP’ By ‘STeP’: FDA Finalizes Accelerated Pathway For Novel Devices, Combo Products
The US FDA released a final guidance document on 5 January that sets in place its new voluntary Safer Technologies Program, or STeP. Modeled after the agency’s burgeoning Breakthrough Devices Program, STeP is for innovative devices and device-led combo products heading for a PMA, 510(k) or de novo regulatory route that aim to treat less serious conditions than devices accepted into the Breakthrough program.
You may also be interested in...
The US Food and Drug Administration’s Total Product Lifecycle Advisory Program pilot, which was authorized under MDUFA V, will begin rolling out next year. The program is designed to speed up the development of innovative medical devices and make them more readily available to patients.
New data from the US FDA shows that neurology and cardiovascular devices are the most likely to be accepted to – and cleared for market via – the breakthrough devices pathway.
Pear Therapeutics is developing the Pear-010 digital therapeutic for virtual reality-delivered pain reduction in adults with acute postoperative and postprocedural pain. Its inclusion in FDA’s Safer Technologies Program (STeP) program suggests the FDA is committed to continuing that program for products that treat non-life-threatening or reversible conditions.